본문으로 건너뛰기
← 뒤로

Contemporary Management of Immune Checkpoint Inhibitor-related Adverse Events.

2/5 보강
Surgical oncology clinics of North America 📖 저널 OA 0% 2023: 0/4 OA 2024: 0/2 OA 2025: 0/1 OA 2026: 0/28 OA 2023~2026 2026 Vol.35(2) p. 415-432 Cancer Immunotherapy and Biomarkers
Retraction 확인
출처
PubMed DOI OpenAlex 마지막 보강 2026-05-01
OpenAlex 토픽 · Cancer Immunotherapy and Biomarkers CAR-T cell therapy research Multiple and Secondary Primary Cancers

Batra A, Tuerff D, Lutzky J

📝 환자 설명용 한 줄

Immune checkpoint inhibitors have become one of the pillars of cancer treatment, but may be associated with a wide range of potential adverse effects.

이 논문을 인용하기

↓ .bib ↓ .ris
APA Akshee Batra, Daniel Tuerff, Jose Lutzky (2026). Contemporary Management of Immune Checkpoint Inhibitor-related Adverse Events.. Surgical oncology clinics of North America, 35(2), 415-432. https://doi.org/10.1016/j.soc.2025.10.010
MLA Akshee Batra, et al.. "Contemporary Management of Immune Checkpoint Inhibitor-related Adverse Events.." Surgical oncology clinics of North America, vol. 35, no. 2, 2026, pp. 415-432.
PMID 41903997 ↗

Abstract

Immune checkpoint inhibitors have become one of the pillars of cancer treatment, but may be associated with a wide range of potential adverse effects. In this review, we discuss the presentation and management of immune-related adverse events according to their severity and organ system involvement. Tables with management guidelines are included.

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

같은 제1저자의 인용 많은 논문 (1)

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반